Elevance Health (NYSE:ELV) Issues FY 2025 Earnings Guidance

Elevance Health (NYSE:ELV) updated its FY 2025 earnings guidance on Saturday. The company provided earnings per share guidance of 34.150-34.850 for the period, compared to the consensus earnings per share estimate of 34.190. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Stephens downgraded shares of Elevance Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $520.00 to $440.00 in a research note on Wednesday, January 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $478.00 target price on shares of Elevance Health in a research report on Wednesday, April 23rd. StockNews.com upgraded shares of Elevance Health from a “hold” rating to a “buy” rating in a research report on Thursday, March 20th. Argus set a $465.00 price objective on Elevance Health in a report on Friday, April 25th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Elevance Health in a report on Friday, March 28th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $510.38.

Elevance Health Stock Performance

Elevance Health stock opened at $409.73 on Monday. Elevance Health has a fifty-two week low of $362.21 and a fifty-two week high of $567.26. The stock has a market cap of $92.57 billion, a price-to-earnings ratio of 16.00, a PEG ratio of 1.18 and a beta of 0.66. The stock’s 50 day simple moving average is $422.21 and its two-hundred day simple moving average is $404.69. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share for the quarter, beating the consensus estimate of $10.60 by $1.37. The company had revenue of $48.77 billion for the quarter, compared to analyst estimates of $46.26 billion. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. As a group, analysts expect that Elevance Health will post 33.96 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Investors of record on Tuesday, June 10th will be given a dividend of $1.71 per share. The ex-dividend date of this dividend is Tuesday, June 10th. This represents a $6.84 dividend on an annualized basis and a yield of 1.67%. Elevance Health’s dividend payout ratio (DPR) is currently 26.69%.

Insiders Place Their Bets

In other news, CAO Ronald W. Penczek sold 443 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $415.13, for a total value of $183,902.59. Following the sale, the chief accounting officer now directly owns 1,847 shares of the company’s stock, valued at approximately $766,745.11. This represents a 19.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of Elevance Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total value of $1,388,635.20. Following the completion of the transaction, the executive vice president now directly owns 10,116 shares of the company’s stock, valued at approximately $4,008,970.80. This represents a 25.73 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,535 shares of company stock worth $3,521,612. 0.29% of the stock is currently owned by company insiders.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.